$USIO

Usio, Inc. (USIO): Results of Operations and Financial Condition

Usio, Inc. (USIO) filed an SEC Form 8-K — Results of Operations and Financial Condition. EX-99.1 2 ex_973961.htm EXHIBIT 99.1 ex_973961.htm Exhibit 99.1 Usio Announces Second Quarter 2026 Financial Results Revenue, Earnings per Share, and Adjusted EBITDA 1 beat Consensus Estimates Revenue up 19% , Adjusted EBITDA 1 up 128% Raises Fiscal 2026 Revenue Guidance, Revenue

Original reporting
Published Aug 12, 2026, 8:00 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 12, 2026, 8:01 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$USIO
Bullish
high confidence
Mentioned
$USIO
Relevance
7/10
alphai data visualization · based on SEC EDGAR 8-K
Decision brief

The 30-second read

$USIOBullishHigh
01

Why it matters

Traders can update models based on the new FY revenue growth range (14% to 16% vs 10% to 12%) and the demonstrated acceleration in revenue and transaction volumes, especially ACH.

02

Market read

Guidance raise plus strong transaction growth (ACH record volume, credit card dollars and transactions up) is the core tradable catalyst.

03

What to watch

Prepaid card services revenue declined 10% year over year, and cash decreased over six months despite liquidity remaining above $6.4 million.

Relevance 7/10Novelty 9/10Timing: after-hours filing on Aug 12, 2026 with raised FY guidance

Background

The company filed an 8-K with Exhibit 99.1 reporting Q2 2026 results and updating FY 2026 revenue expectations.

Company-level read

Ticker impact

$USIOBullishHigh confidence
Context

Usio reported Q2 2026 revenue up 19% and Adjusted EBITDA up 128%, and raised full-year revenue guidance to 14% to 16% growth.

Expected impact

Near-term bias higher as guidance raise and margin/EBITDA acceleration can re-rate the stock, subject to follow-through in subsequent quarters.

Evidence & confidence

The filing is a primary earnings/guidance disclosure with multiple growth metrics (revenue, transactions, ACH record volume) and a specific updated FY range.

Market effects

Supports the narrative of improving profitability in fintech payment processors, particularly in higher-margin ACH and payfac models.

Limited, company-specific impact likely confined to small/mid-cap fintech sentiment.

Low, no cross-border regulatory or macro catalyst mentioned.

Counterpoint

Gross margin is down year over year (24.2% vs 25.8%), and interest revenue declined, so the EBITDA surge may not fully translate into sustainable margins.

Key entities

  • Usio, Inc.

    Nasdaq-listed fintech payments provider reporting Q2 2026 results and raising FY 2026 revenue guidance.

  • Louis Hoch

    President and CEO who commented on growth and profitability improvements in the quarter.

Related articles

$USIOMed

Usio (USIO) Q2 2026 Earnings Call Transcript

Usio (USIO) reported Q2 2026 revenue of $23.7M, up 19%, with net income of $280K. Key growth areas include credit card (28%) and ACH (21%). The company raised fiscal 2026 revenue guidance to 14-16% growth. Management highlighted PayFac's 43% growth and upcoming Usio Ion platform rollout, expected to increase daily cash float to $300M.

$GILDHighAI 8/10

Gilead’s Core Business Is Accelerating, But Will Its $11 Billion Pipeline Bet Pay Off?

Gilead Sciences (GILD) reported Q2 2026 with double-digit growth in commercial portfolio sales, but posted a significant loss due to $11.2B in R&D expenses from acquisitions. HIV sales rose 12% to $5.7B, while non-HIV areas like liver disease and cancer treatments also showed growth. The company raised its 2026 sales guidance and made strategic acquisitions, but faces risks from clinical development and financial obligations.

$ABBVMedAI 8/10

AbbVie’s Humira Replacement Strategy Is Working, But Could Growth Be Too Concentrated?

AbbVie (NYSE:ABBV) reported Q2 2026 revenue of $16.99B, up 10.2%, driven by immunology and neuroscience. Skyrizi and Rinvoq revenues grew 24.4% and 24.5% respectively, offsetting Humira's 35.9% decline. However, concentration risk exists as these two products made up 47% of revenue. Oncology and aesthetics showed weaker performance, with oncology revenue down 1.5%. Adjusted EPS rose 22.9% to $3.65.